MX2023002947A - Composiciones y métodos para el tratamiento de distrofias musculares. - Google Patents
Composiciones y métodos para el tratamiento de distrofias musculares.Info
- Publication number
- MX2023002947A MX2023002947A MX2023002947A MX2023002947A MX2023002947A MX 2023002947 A MX2023002947 A MX 2023002947A MX 2023002947 A MX2023002947 A MX 2023002947A MX 2023002947 A MX2023002947 A MX 2023002947A MX 2023002947 A MX2023002947 A MX 2023002947A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- muscular dystrophies
- treating muscular
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077329P | 2020-09-11 | 2020-09-11 | |
| US202163148823P | 2021-02-12 | 2021-02-12 | |
| PCT/US2021/049362 WO2022055926A1 (en) | 2020-09-11 | 2021-09-08 | Compositions and methods for treating muscular dystrophies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002947A true MX2023002947A (es) | 2023-06-06 |
Family
ID=80630037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002947A MX2023002947A (es) | 2020-09-11 | 2021-09-08 | Composiciones y métodos para el tratamiento de distrofias musculares. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230348394A1 (https=) |
| EP (1) | EP4211131A4 (https=) |
| JP (1) | JP2023541040A (https=) |
| KR (1) | KR20230067637A (https=) |
| AU (1) | AU2021341960A1 (https=) |
| CA (1) | CA3192071A1 (https=) |
| CL (1) | CL2023000698A1 (https=) |
| CO (1) | CO2023004447A2 (https=) |
| IL (1) | IL301122A (https=) |
| MX (1) | MX2023002947A (https=) |
| SA (1) | SA523442922B1 (https=) |
| WO (1) | WO2022055926A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023007133A (es) | 2020-12-17 | 2023-06-27 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos. |
| EP4705297A1 (en) * | 2023-05-03 | 2026-03-11 | The Regents Of The University Of California | Small molecule therapy for duchenne muscular dystrophy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3514490B2 (ja) * | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法 |
| LT2502911T (lt) * | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2008059214A1 (en) * | 2006-11-13 | 2008-05-22 | Astrazeneca Ab | Bisamlde derivatives and use thereof as fatty acid synthase inhibitors |
| GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| US20120184548A1 (en) * | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| CN108430992A (zh) * | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| CA3057431A1 (en) * | 2017-03-24 | 2018-09-27 | Taisho Pharmaceutical Co., Ltd. | 2(1h)-quinolinone derivative |
| US11065243B2 (en) * | 2017-10-27 | 2021-07-20 | Sonic Master Limited | Inhibitors of DUX4 induction for regulation of muscle function |
| WO2019236677A1 (en) * | 2018-06-05 | 2019-12-12 | The Regents Of The University Of California | Methods for treating muscular dystrophies |
-
2021
- 2021-09-08 KR KR1020237011841A patent/KR20230067637A/ko active Pending
- 2021-09-08 EP EP21867476.0A patent/EP4211131A4/en active Pending
- 2021-09-08 MX MX2023002947A patent/MX2023002947A/es unknown
- 2021-09-08 WO PCT/US2021/049362 patent/WO2022055926A1/en not_active Ceased
- 2021-09-08 JP JP2023515741A patent/JP2023541040A/ja active Pending
- 2021-09-08 IL IL301122A patent/IL301122A/en unknown
- 2021-09-08 AU AU2021341960A patent/AU2021341960A1/en active Pending
- 2021-09-08 CA CA3192071A patent/CA3192071A1/en active Pending
- 2021-09-08 US US18/025,747 patent/US20230348394A1/en active Pending
-
2023
- 2023-03-10 CL CL2023000698A patent/CL2023000698A1/es unknown
- 2023-03-12 SA SA523442922A patent/SA523442922B1/ar unknown
- 2023-04-11 CO CONC2023/0004447A patent/CO2023004447A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230067637A (ko) | 2023-05-16 |
| IL301122A (en) | 2023-05-01 |
| AU2021341960A1 (en) | 2023-04-20 |
| SA523442922B1 (ar) | 2024-08-25 |
| JP2023541040A (ja) | 2023-09-27 |
| CA3192071A1 (en) | 2022-03-17 |
| US20230348394A1 (en) | 2023-11-02 |
| CL2023000698A1 (es) | 2023-10-30 |
| WO2022055926A1 (en) | 2022-03-17 |
| EP4211131A4 (en) | 2025-01-15 |
| EP4211131A1 (en) | 2023-07-19 |
| CO2023004447A2 (es) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| PH12020550857A1 (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| SA520412543B1 (ar) | تركيبات وطرائق لعلاج السرطان والاضطرابات المناعية باستخدام جراثيم الفيونيلّة | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| SA523442922B1 (ar) | تركيبات وطرق لعلاج حالات الحثل العضلي | |
| GEP20237541B (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| MX359626B (es) | Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial. | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| PH12021552588A1 (en) | Cd73 inhibitors | |
| PH12020550583A1 (en) | Use of riluzole prodrugs to treat ataxias | |
| MX2021005245A (es) | Composiciones de oligosacaridos y metodos de uso de las mismas. | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| WO2021067611A3 (en) | Compositions and methods for treating alzheimer's disease | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| MX2024006105A (es) | Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects |